Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Correction to ‘Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway’
Saved in:
| Published in: | FEBS Open Bio |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Correction to ‘Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway’
- Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
- Repurposing dihydroartemisinin as a novel anticancer agent against colorectal cancer stem cells
- Distinct target genes and effector processes appear to be critical for p53-activated responses to acute DNA damage versus p53-mediated tumour suppression
- Identifying gene expression signatures for risk stratification of postoperative adjuvant chemotherapy in colorectal cancer
- Autocrine motility factor peptide enhances curcumin/tetrahydrocurcumin activity against colorectal cancer cells in association with glucose-6-phosphate dehydrogenase downregulation and oxidative stress
- Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling